New FDA-Approved Treatment for RKD

The FDA has approved Ultomiris for adults with Nefropatía por IgA (IgAN). More information coming soon. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

INICIO / RESULTADOS DE LA BÚSQUEDA

Resultados de la búsqueda

Temas

tipo de enfermedad

Recursos

Mostrando 1-3 de 5 resultados para:

The FDA Grants Accelerated Approval of ULTOMIRIS (ravulizumab-cwvz) for Adults with IgA Nephropathy

October 2026 — NephCure celebrates another landmark milestone for the rare kidney disease (RKD) community following the U.S. Food and Drug Administration’s (FDA) accelerated approval of ULTOMIRIS® (ravulizumab-cwvz) as the first and only C5 ... Leer más

NephCure Applauds U.S. Department of Health and Human Services on the Release of the Rare Kidney Disease Inclusive Kidney Care National Plan

PHILADELPHIA, PA — October 22, 2026 — NephCure, a leading nonprofit organization advocating to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments ... Leer más

NephCure Celebrates C3G Awareness Day on September 25, 2026

NephCure, a leading nonprofit organization advocating to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome ... Leer más

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.